Impact News +++ OHB: Auftrag von knapp 1 Mrd EUR bei europ Satellitenkommunikationssystem (Dow Jones) +++ OHB Aktie +4,06%

BIOMARIN Aktie

>BIOMARIN Aktienkurs

57.5 EUR +3.0% (TradegateBSX)

Ask: 58 EUR / 99 Stück

Bid: 56 EUR / 100 Stück

Tagesumsatz: 6 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

BIOMARIN Aktie über LYNX handeln

Intraday

1 Jahr

>BIOMARIN Performance

1 Woche: -4,5%

1 Monat: +2,0%

3 Monate: +23,0%

6 Monate: +4,8%

1 Jahr: +12,1%

laufendes Jahr: +8,9%

>BIOMARIN Aktie

Profil:

Biomarin Pharmaceutical Inc. is a global biotechnology company specializing in therapies for rare, genetically defined diseases. The company focuses on developing and commercializing targeted treatments that address the underlying biology of serious ..
>Volltext..

Insiderhandel:

>BIOMARIN Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>BIOMARIN Peer Group

Gesundheit, Neurologische Erkrankungen/ Schlaganfälle, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>BIOMARIN Chart & Kurs - NASDAQ

>BIOMARIN News

31.08.26 - 08:06	BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea (PR Newswire)
	Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and......

19.08.26 - 21:24	BioMarin initiated an outperform at BMO as Voxzogo erosion overstated (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.08.26 - 18:15	BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment (Zacks)
	BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline....

19.08.26 - 14:06	IN BRIEF: RTW Biotech Opportunities get 0.2% uplift from Alesta deal (Alliance)
	RTW Biotech Opportunities Ltd - investor in life sciences sector - Notes the announcement by BioMarin Pharmaceuticals Inc...

18.08.26 - 15:24	BioMarin Aktie: Übernahme von Alesta Therapeutics beflügelt den Kurs (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

18.08.26 - 15:24	BioMarin Aktie legt nach 275-Millionen-Dollar-Deal zur Übernahme von Alesta zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

18.08.26 - 14:57	BioMarin to gain hypophosphatasia drug under Alesta buyout (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.26 - 13:00	Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries (Zacks)
	Five stocks stand out as potentially undervalued by price-to-book measures, including BioMarin Pharmaceutical, Invesco and Centene....

13.08.26 - 16:45	5 Undervalued Price-to-Book Stocks Worth Buying in August (Zacks)
	BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios....

12.08.26 - 17:30	Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High? (Zacks)
	The mean of analysts' price targets for BioMarin (BMRN) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....

12.08.26 - 15:06	BioMarin auf Wachstumskurs: Amicus-Übernahme beschleunigt Umsatz und Schuldenabbau (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.08.26 - 15:09	BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston (PR Newswire)
	SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston. An audio webcast of the presentation will be......

07.08.26 - 01:45	Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics (Zacks)
	While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

07.08.26 - 01:00	BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
	BioMarin (BMRN) delivered earnings and revenue surprises of +25.00% and +7.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...

07.08.26 - 00:54	BioMarin übertrifft Prognosen für Q2 2026 und hebt Ausblick an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.08.26 - 17:21	BioMarin Pharmaceutical Q2 2026 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.07.26 - 12:00	BioMarin and n-Lorem partner on early research for ReNU syndrome therapy (PBR)
	ReNU syndrome is a rare neurodevelopmental disorder that is caused by variants in the RNU4-2 gene. The agreement aims to address an estimated 75% of ReNU syndrome cases. The post BioMarin and n-Lorem partner on early research for ReNU syndrome therapy appeared first on Pharmaceutical Business review....

27.07.26 - 17:31	Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for (Zacks)
	BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

27.07.26 - 16:33	BioMarin, n-Lorem Foundation to collaborate on ReNU syndrome treatment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.07.26 - 15:09	BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome (PR Newswire)
	ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense expertise Investigational antisense oligonucleotide (ASO) aims to address the underlying genetic......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein Bauer, der den ganzen Wald schlägert, ist auf dem Holzweg. - Dr. Fritz P. Rinnhofer

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram